Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: 2-year data from a phase 3 clinical trial

• F. De Benedetti: Abbott, BMS, Novartis, Novimmune, Pfizer, Roche Pharmaceuticals, SOBI • N. Ruperto: Abbott, ACRAF, BMS, Centocor, Novartis, Pfizer, Roche Pharmaceuticals, Xoma • G. Horneff: Abbott, Chugai, Novartis, Pfizer, Roche Pharmaceuticals • K. Onel: Merck, Roche Pharmaceuticals • J. Frane: Consultant to Genentech and to Ipsen Biopharmaceuticals • A. Kenwright: Roche Pharmaceuticals • K. N. Bharucha: Genentech • A. Martini: Abbott, ACRAF, BMS, Centocor, Novartis, Pfizer, Roche Pharmaceuticals, Xoma • D. Lovell: Abbott, Amgen, Arthritis and Rheumatism, Astra-Zeneca, BMS, Centocor, Forest Research, Genentech, Hoffmann-La Roche, National Institutes of Health, Novartis, Pfizer, Regeneron, UCB, Wyeth, Xoma • G. Espada, V. Gerloni, B. Flato, B. Myones, T. H. Lipman: Nothing to disclose 2